PROFILE

Mark is an experienced ASX listed, CFO and non-executive director. His executive career spans senior finance leadership roles with major ASX listed companies such as Cochlear, Aristocrat, Coca-Cola Amatil and Goodman Fielder.  Currently, he serves as a non-executive director and chair of the Audit and Risk Committee of Opyl Limited, an ASX listed AI technology business focused on life sciences. Previously, he was non-executive director and chair of Respiri Limited, an eHealth SaaS company, and non-executive director and chair of the Audit and Risk Committee of Orcoda Limited, a SaaS based technology company. 

Mark commenced his career with EY, working in business advisory, tax and management consulting.  His most recent executive roles include, CFO and Company Secretary for Wiseway Group Limited (who he successfully led through an IPO and listing on ASX) and CFO of listed global medtech company Anteris Technologies Limited.  Prior to this, Mark was Director of Finance and IT for Asia Pacific at Cochlear.

He has a strong track record of delivering growth and improvement across multiple industry sectors (medtech/health, technology, consumer) and geographies (Americas, Europe, Oceania).  Mark has also worked extensively in Asia for more than 25 years.  His strong finance and operations credentials are complemented by extensive strategy, M&A, corporate finance, investor relations, risk management and governance expertise.  Much of Mark’s work has involved guiding and supporting high growth and early stage companies.